Health Catalyst Q3 adjusted EBITDA beats estimates, reaffirms 2025 revenue guidance

Health Catalyst

10/11/2025 21:14

Overview

Health Catalyst Q3 2025 revenue remains flat year-over-year at $76.3 mln

Adjusted EBITDA for Q3 2025 beats analyst expectations

Net loss for Q3 2025 widens to $22.2 mln from $14.7 mln last year

Outlook

Health Catalyst expects Q4 2025 revenue of $73.5 mln

Company anticipates Q4 2025 adjusted EBITDA of $13.4 mln

Health Catalyst reaffirms full-year 2025 revenue guidance at $310 mln

Result Drivers

STRATEGIC FOCUS - Co attributes results to focus on high-impact solutions with proven ROI

COST MANAGEMENT - Improved gross margin attributed to cost management efforts

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$76.32 mln
Q3 Net Income
-$22.23 mln
Q3 Adjusted EBITDA
Beat
$12 mln
$10.70 mln (12 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the software peer group is "buy."

Wall Street's median 12-month price target for Health Catalyst Inc is $4.00, about 29.3% above its November 7 closing price of $2.83

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nGNX8ZfV52

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)